Newsbenzinga
Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
· Published
Article summary
Vir Biotechnology and Gilead collaborate on novel T-cell engagers for solid tumors in a deal worth up to $1.87 billion, plus royalties.
An excerpt from the original article.
Comments —
Loading comments…